FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered™ investigational drug-device combination product for the acute treatment of migraine.

As previously reported, the 505(b)(2) NDA for AVP-825 includes clinical data developed by OptiNose including a pivotal phase III controlled clinical trial, a supportive phase II controlled clinical trial and two pharmacokinetic studies. The NDA also references data from the extensive clinical use of sumatriptan over the past 20 years.

The acceptance of the NDA indicates that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) V goal date is November 26, 2014.

SOURCE OptiNose

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers show existence of particular type of sphincter in the brain's blood supply